Axial Spondyloarthritis (Ankylosing Spondylitis)
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis (COAST-W)
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in participants with radiographic axial spondyloarthritis (rad-axSpA) who have taken tumor necrosis factor (TNF) inhibitor.
Your participation could last up to 1.5 years and include 15 visits to the study center. After this study, you may be eligible to enter another study that could last up to 2 more years.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Participant must be diagnosed with radiographic axial spondyloarthritis (rad-xSpA) with inflammation of the sacroiliac joint or region
Participant must be able to walk
Participant must have a history of back pain greater than or equal to 3 months which began at age 45 or younger
Participants must have a history of prior therapy for axSpA of at least 12 weeks prior to starting the study. Examples of prior therapy may include but are not limited to physical therapy, NSAID, and TNF inhibitor treatment
Participant must have had prior treatment with at least 1 but no more than 2 TNF inhibitors
Participant must not received a live vaccine within 12 weeks or received a vaccine with Bacillus Calmette-Guerin (BCG) within the past year
Participant must not have had major surgery within 8 weeks of baseline and will not require surgery during the study
Female participant must not be pregnant or breastfeeding